Preclinical study discovered that when administrated at pico- to nanomolar concentrations, HDP-101 exhibited profound cytotoxicity to BCMA+ myeloma cell lines and non-proliferating primary MM cells isolated from patients with RRMM irrespective of BCMA expression level. Here, TNFRSF17 is linked to plasma cell myeloma.